Clinical Trial Update: Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of LP-284 in adults with relapsed or refractory lymphomas and advanced solid tumors, focusing on safety, pharmacokinetics, and pre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• LP-284 (LP-284)

Snippet

Sponsor: Lantern Pharma Inc. | Conditions: Relapsed or Refractory Lymphomas, Advanced Solid Tumor | Phase 1 | Status: RECRUITING